Introduction
============

Endothelium, as the major regulator of vascular homeostasis, exerts a number of vasoprotective effects, by maintaining the balance between vasodilation and vasoconstriction, inhibition and stimulation of smooth muscle cell proliferation and migration, and thrombogenesis and fibrinolysis ([@b38-vhrm-4-1439]; [@b17-vhrm-4-1439]). Many of these effects are largely mediated by nitric oxide (NO), the most potent endogenous vasodilator. A defect in the synthesis, release, or activity of nitric oxide leads to endothelial dysfunction, an early marker for atherosclerosis ([@b4-vhrm-4-1439]). Endothelial function can be easily measured noninvasively with Doppler ultrasonography by assessing flow-mediated dilation (FMD) in the brachial artery after transient vascular occlusion ([@b14-vhrm-4-1439]; [@b6-vhrm-4-1439]). FMD serves as an index of NO bioavailability and vascular health.

The rapidly growing South Asian population in United States has one of the world's highest rates of endothelial dysfunction, metabolic syndrome and premature coronary artery disease (CAD) irrespective of region, religion, gender, and education. This may be a result of genetic predisposition to high levels of lipoprotein (a), small coronary arteries, low birth weight, in addition to environmental, nutritional and lifestyle factors ([@b2-vhrm-4-1439]; [@b20-vhrm-4-1439]).

Epidemiological studies and clinical trials indicate that the intake of very-long-chain n-3 polyunsaturated fatty acids (omega-3 PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduces the risk of cardiovascular mortality ([@b3-vhrm-4-1439]; [@b28-vhrm-4-1439]; [@b18-vhrm-4-1439]). The cardioprotective effects of omega-3 PUFAs are widespread and are mediated by several mechanisms, which include decreasing triglyceride levels, increasing HDL levels, antiinflammatory properties, antithrombotic properties, antiarrhythmic properties and endothelial relaxation properties ([@b7-vhrm-4-1439]; [@b5-vhrm-4-1439]).

Statins, potent inhibitors of cholesterol biosynthesis, are indicated in the primary and secondary prevention of CAD. Their overall benefits suggest effects beyond cholesterol lowering that involve improving endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation and inhibiting the thrombogenic response ([@b24-vhrm-4-1439]).

The effect of a combined therapy of statins plus omega-3 PUFAs on endothelial function in a South Asian population, particularly at high risk for premature CAD, has not been investigated so far. We designed a randomized controlled cross-over study to test the hypothesis that omega-3 PUFAs intake plus rosuvastatin improves endothelial function in South Asians with dyslipidemia.

Methods
=======

Study population
----------------

South Asian subjects (originating or having ancestry from India, Pakistan, or Bangladesh) now living in the New York metropolitan area were recruited for a protocol approved by our Institutional Review Board. Informed consent was obtained from each patient and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. To be eligible for the screening phase of the study, the subjects had to be 25 to 80 years old, and have a diagnosis of dyslipidemia, defined for the purpose of this study as a plasma low-density lipoprotein (LDL) cholesterol \>100 mg/dl, and/or plasma triglyceride \>150 mg/dl, with or without established CAD. All subjects deemed eligible after the screening phase underwent endothelial function assessment including endothelium-dependent vasodilation (EDV) and endothelium-independent vasodilation (EIV) with brachial artery ultrasound, as described below. Those who had an abnormal endothelial function, defined as an EDV less than 7%, were retained for the active phase of the study. Healthy arteries typically show an increase in diameter in the range of 5% to 20%.

Study design
------------

After the initial endothelial function assessment, patients were randomized in a crossover design between 2 drug regimens: rosuvastatin 10 mg along with omega-3 fatty acid supplements (Fish oil capsules 4.53 g DHA/EPA, N3 Oceanic Inc., Palm, PA, USA) (Group 1) or rosuvastatin 10 mg alone (Group 2) as shown in [Figure 1](#f1-vhrm-4-1439){ref-type="fig"}. After 4 weeks, the omega-3 PUFAs supplements were removed from the treatment of Group 1 and added to the subjects in Group 2. Each patient served as his own control. The omega-3 fatty acid supplement capsules contained 430 mg EPA, 325 mg DHA, gelatin, glycerine, purified water, and natural lemon flavor as other ingredients. Subjects received 2 capsules three times per day. Patients taking statin medication were asked to stop that medication for four weeks before entering the study. All subjects maintained the same medication other than the study medication throughout the duration of the study. Compliance with the medication was assessed by pill count at each visit and at the end of the study.

Assessment of endothelium-dependent and endothelium-independent vasodilation
----------------------------------------------------------------------------

The endothelial function was evaluated according to the guidelines for the ultrasound assessment of flow-mediated vasodilatation of the brachial artery ([@b6-vhrm-4-1439]), as previously described from our laboratory ([@b1-vhrm-4-1439]; [@b32-vhrm-4-1439]). Although no gold standard for the measurement of endothelial function exist, the measurement of flow-mediated vasodilation in the brachial artery, assessed with Doppler ultrasound, has become the clinical technique of choice for the evaluation of endothelial function. The method was validated and widely used in numerous clinical studies ([@b14-vhrm-4-1439]; [@b31-vhrm-4-1439]; [@b10-vhrm-4-1439]). All measurements were performed early in the morning. Subjects were requested to abstain from any food or drink for at least 8 hours (overnight) and not use tobacco on the morning of the evaluation. All vasoactive medication was withheld on the morning of the study. On arrival subjects were allowed to rest in a supine position for 20 minutes. Baseline blood pressure and heart rate were recorded and blood was collected from the antecubital vein. This was followed by an *in vivo* assessment of endothelial function by using ultrasonography to measure the brachial artery diameter at rest, during reactive hyperemia (leading to flow-mediated endothelium-dependent vasodilatation), and after administration of 0.4 mg of sublingual nitroglycerin (an endothelium-independent vasodilator). After baseline imaging was performed by scanning the brachial artery in a longitudinal fashion, a pneumatic cuff was inflated around the right forearm to 50--60 mmHg above the systolic pressure (≈200 mmHg) for 5 minutes. The cuff was then released and the artery continuously imaged for 5 minutes. After an additional 5 minutes of recuperation, a new baseline imaging was obtained followed by the administration of 0.4 mg nitrogycerin and continuously imaging for other 5 minutes. Flow-mediated endothelium dependent vasodilation (EDV) was calculated by dividing the maximum vessel diameter at 50 to 60 seconds after cuff deflation by the average baseline diameter. Endothelium-independent vasodilation (EIV) was measured as the maximum vessel diameter at 3 to 4 minutes after nitroglycerin administration divided by average baseline diameter. The arterial diameter was measured by using ultrasonic calipers for 4 cardiac cycles for each condition and then averaged. Flow-mediated vasodilation was expressed as the absolute change in diameter (in millimeters), and as the percent increase in diameter from baseline. All ultrasonographic scans were obtained by the same operator using the same equipment (Acuson L10 6- to 11-MHz transducer and Acuson Aspen System). All brachial artery scans were read by the same experienced ultrasonographer and validated by a second independent reader, both of whom were blinded to both the identity of the participants as well as the stage of the experiment. Across 100 observations performed in our laboratory by 2 observers, a diameter difference of 0.2 mm was estimated correctly in 72% of the cases. There was an interobserver variability of 0.1 mm in 28% of the cases. There was no difference larger than 0.2 mm between the 2 observers. The intraobserver variability was 0.82.

Laboratory measurements
-----------------------

Fasting blood samples were obtained at baseline and at the end of each drug regimen (Week 4 and Week 8). Plasma analysis for the lipid profile, fasting glucose, C-reactive protein (CRP), hemoglobin A~1~C (Hb A~1~C), erythrocyte sedimentation rate (ESR), and fibrinogen was done in the hospital's clinical laboratory. For the rest of the studies blood was collected in Vacutainer tubes for serum separation and centrifuged at 3000 rpm for 15 minutes (4 °C). The serum was collected and stored at −70 °C until use.

Adiponectin ELISA
-----------------

Adiponectin concentrations in serum samples of patients participating in the study were measured using an ELISA kit (Linco Research, St. Charles, MO, USA) according to the manufacturer's instructions. Serum samples were diluted 500 times in the assay diluent buffer before analysis in order to fall within the dynamic range of the assay.

Statistical analysis
--------------------

Analyses were performed with SPSS software (version 10.0; SPSS Inc., Chicago, IL, USA). Sample size calculations indicated that, to detect a mean difference in EDV of 2% on the study medication, using a croos-over design, 16 subjects would need to complete the study (α statistic, 0.05; power \>0.8). Data are presented as mean ± SD. Wilcoxon signed-rank test was used to compare changes in outcome variables for endothelial function in response to treatment or with the wash out period. Paired or unpaired t test or chi square test were used to compare demographic baseline characteristics and laboratory values. Statistical significance was set for p \< 0.05.

Results
=======

Thirty of thirty-four screened subjects completed the study. Three subjects failed to fulfill eligibility criteria (endothelial function within normal range) and one was lost to follow-up. The study medication was well tolerated by all subjects and no bleeding or muscle symptoms were reported. Their mean age was 51 (range, 27 to 78 years). Their demographic and metabolic characteristics are summarized in [Table 1](#t1-vhrm-4-1439){ref-type="table"}. The complete results of the assessment of the endothelial function are summarized in [Table 3](#t3-vhrm-4-1439){ref-type="table"}. For subjects in Group 1 (n = 14), compared to baseline, omega-3 PUFAs plus rosuvastatin improved endothelial-dependent vasodilation (EDV: −1.42% to 11.36%, p = 0.001) ([Figure 2](#f2-vhrm-4-1439){ref-type="fig"}), and endothelial-independent vasodilation (EIV: 3.4% to 17.37%, p = 0.002) ([Figure 3](#f3-vhrm-4-1439){ref-type="fig"}). When omega-3 PUFAs were removed, these effects were lost (EDV: 11.36% to 0.59%, p = 0.003) ([Figure 2](#f2-vhrm-4-1439){ref-type="fig"}). In Group 2 (n = 16), rosuvastatin alone failed to improve both EDV (−2.49% to −0.66%, p = 0.48) and EIV (10.31% to 11.02%, p = 0.6) compared to baseline. However, when omega-3 PUFAs were added to rosuvastatin, there was a significant improvement in EDV (−0.66% to 14.73%, p = 0.001) ([Figure 2](#f2-vhrm-4-1439){ref-type="fig"}) and EIV (11.02% to 24.5%, p = 0.001) ([Figure 3](#f3-vhrm-4-1439){ref-type="fig"}). Addition of omega-3 PUFAs further improved the lipid profile in both groups ([Figure 4](#f4-vhrm-4-1439){ref-type="fig"}). In group 1 total cholesterol decreased from 191 to 153 mg/dl (p = 0.001), triglycerides from 139 to 91 mg/dl (p = 0.006), and LDL 116 to 88 mg/dl (p = 0.014). In group 2 total cholesterol decreased from 184 to 139 mg/dl (p \< 0.001), triglycerides from 141 to 103 mg/dl (p = 0.013), and LDL from 109 to 76 mg/dl (p = 0.002). There were no significant differences in the CRP, ESR, and fibrinogen levels ([Table 2](#t2-vhrm-4-1439){ref-type="table"}). Nevertheless a tendency of decreasing in ESR was noted in group 2 without reaching statistical significance. Neither rosuvastatin nor the combination treatment affected the levels of adiponectin ([Table 2](#t2-vhrm-4-1439){ref-type="table"}).

Discussion
==========

This study illustrates that the addition of omega-3 PUFAs to rosuvastatin in a high-risk population (South Asians) with dyslipidemia improves EDV and EIV as well as the lipid profile. Withdrawal of omega-3 PUFAs treatment is associated with a return of the endothelial function back to the baseline, in spite of continuing the treatment with rosuvastatin.

Several studies have shown that South Asians are an emerging risk group for CAD as compared with other ethnicities ([@b2-vhrm-4-1439]; [@b20-vhrm-4-1439]). Numerous factors, including a high prevalence of conventional risk factors (smoking, diabetes, hypertension, etc.), insulin resistance, metabolic syndrome, low birth weights, and genetic predisposition, have been shown to be responsible for this. The INTERHEART case-control study found that the population-attributable risk in the South Asian region is 58.7% for dyslipidemia, 37.4% for smoking, 37.7% for abdominal obesity, 29.6% for hypertension, 11.8% for diabetes, and 15.9% for psychological risk factors ([@b39-vhrm-4-1439]). Our study group was representative of this high-risk population: 100% of patients were dyslipidemic, 90% had metabolic syndrome (as defined by the ATP III criteria. ([@b27-vhrm-4-1439]), 70% had established CAD, 70% had hypertension, and 33% had a diagnosis of diabetes mellitus. Ninety percent of the patients screened for this study had severe endothelial dysfunction displaying a non-response or a vasoconstrictive response to shear stress. No studies to date have evaluated the effect of statins or omega-3 PUFAs on the endothelial function in this population.

Endothelial dysfunction is thought to be an early and important event in the development of many cardiovascular diseases including atherosclerosis, hypertension, and heart failure. The precise mechanism of endothelial dysfunction is not completely understood, but it is generally believed to be mediated by NO produced by the endothelial cells. Other mediators such as prostanoids are also involved. The potential for reversal of endothelial dysfunction with different therapies has generated considerable interest. Previous studies have yielded conflicting results about the effect of statins on endothelial function. Several studies report that statin therapy improves endothelial-dependent vasodilation in hypercholesterolemic patients ([@b23-vhrm-4-1439]; [@b35-vhrm-4-1439]; [@b11-vhrm-4-1439]). A number of mechanisms have been proposed to explain these effects. One important pathway appears to be the effects of statins on NO production via increased availability of endothelial nitric oxide synthase (eNOS). Thus, statins prevent the downregulation of eNOS mRNA by oxidized-LDL, hypoxia, and TNF-α ([@b21-vhrm-4-1439]; [@b22-vhrm-4-1439]). Additionally HMG-CoA inhibition results in the activation of protein kinase Akt and the posttranslational phosphorylation of the eNOS protein ([@b9-vhrm-4-1439]; [@b16-vhrm-4-1439]). Nevertheless, other studies, particularly in subjects with type II diabetes, but also in patients with familial hypercholesterolemia, report no effect at all ([@b30-vhrm-4-1439]; [@b36-vhrm-4-1439]; [@b37-vhrm-4-1439]; ter [@b34-vhrm-4-1439]). The reason for this inconsistency is unclear but could be related to the dependency of endothelial function on insulin resistance. There is also the possibility of a particular resistance to statins in South Asians and this finding deserves further investigation. Also, we cannot exclude a delayed vasodilative effect of rosuvastatin, but this is unlikely, as other studies have demonstrated a very early onset of the statin activity ([@b29-vhrm-4-1439]). Similar findings have been reported by ter [@b34-vhrm-4-1439] who showed no effect of rosuvastatin on endothelial function, in spite of a clear effect on the lipid profile and inflammatory markers.

Long-chain omega-3 PUFAs, found in fatty fish and fish oil have cardiovascular protective properties. They cause endothelial relaxation and promote vascular compliance ([@b19-vhrm-4-1439]; [@b33-vhrm-4-1439]). Our study supports an early and consistent improvement in endothelium-dependent dilatation with treatment with the omega-3 PUFAs in South Asian patients with dyslipidemia treated with rosuvastatin ([Figure 5](#f5-vhrm-4-1439){ref-type="fig"}). These findings extend prior observations that omega-3 PUFAs improve endothelium-dependent dilatation in hypercholesterolemic patients ([@b13-vhrm-4-1439]). The effect may be due particularly to the DHA component of the fish oil capsules ([@b26-vhrm-4-1439]). The mechanism is not fully understood, but omega-3 PUFAs may protect against vasospasm and thrombosis by enhancing NO release, and prostacyclin synthesis, and by suppressing thromboxane formation ([@b25-vhrm-4-1439]).

Previously, it was proposed that omega-3 PUFAs mediate the actions of various statins and states of essential fatty acids deficiency are accompanied by an increased HMG-CoA reductase activity, making statins unable to lower plasma lipid levels ([@b8-vhrm-4-1439]). These observations could explain why we found the improvement of endothelial function in the presence of omega-3-PUFAs.

The present study showed, for the first time, that omega-3 PUFAs improved endothelial function in a group of subjects who appeared resistant to the vasoprotective effect of rosuvastatin. These findings support a therapeutic strategy where omega-3 PUFAs should be added to a statin, particularly if the endothelial function fails to improve.

Flow-mediated dilatation of the brachial artery correlates well with coronary response to the endothelium-dependent vasodilator acetylcholine. Therefore, the use of omega-3 PUFAs supplements might possibly represent another therapeutic modality for patients with known, or at risk for coronary artery disease.

Our study confirms prior reports from animal models showing omega-3 fatty acid supplementation improves EIV ([@b12-vhrm-4-1439]). The improvement in EIV was seen in both groups but only as an effect of omega-3 PUFAs ([Figure 3](#f3-vhrm-4-1439){ref-type="fig"}). The removal of omega-3 PUFAs from the treatment returned the EIV towards baseline. [@b12-vhrm-4-1439] reported that in aortic rings from spontaneously hypertensive rats and Wistar--Kyoto rats, EPA and DHA induced endothelium-dependent and-independent vasodilation, respectively. These may be attributable to direct and indirect effects of DHA on the arterial wall. The selective incorporation of DHA into endothelial membranes could increase membrane fluidity, calcium influx, and endogenous synthesis and NO release. Although we did not see a significant effect on the systolic or diastolic blood pressure, possibly because of the small sample size, EIV seems to be responsible for the improvement in blood pressure control with omega-3 PUFAs reported by others ([@b26-vhrm-4-1439]).

This study is the first to show that the benefits of omega-3 PUFAs are rapidly lost with the withdrawal of treatment. Within 4 weeks of removal of omega-3 PUFA, the improvement in endothelial function was lost and the endothelial function, as measured by the EDV, returned to levels similar to the baseline. Moreover, this significant change in endothelial function was accompanied by worsening of EIV.

The use of statins is the standard of care for patients with dyslipidemia and at high risk for CAD. The study subjects exhibited an appropriate response to rosuvastatin (17%--25% reduction in LDL levels), which also confirms their compliance with the study medication. The addition of omega-3 fatty acid supplements to rosuvastatin led to further decreases in LDL values and significant decrease in the triglycerides levels. Nevertheless, none of the changes in the lipid profile correlated to the change in the EDV/EIV, suggesting that the effect of omega-3 PUFAs on endothelial vasodilation is mediated via other mechanisms. Although there are reports of an effect of omega-3 PUFAs on the level of adiponectin in rats ([@b15-vhrm-4-1439]) we found no significant alteration in the serum levels of adiponectin in our group of patients.

This study is limited particularly by the small sample size and by the relatively short period of treatment. Should these patients be treated longer, we could have possibly seen an effect of the rosuvastatin on the endothelial function. Nevertheless, it is encouraging to see an early and strong effect of omega-3 PUFA when added to the statin. Other limitation of our study is the lack of control group treated with omega-3-PUFAs only. Although our findings strongly suggest that the improvement of endothelial function is due mainly to the omega-3-PUFAs, the results would have been more decisive having that control group.

In conclusion the addition of omega-3 PUFAs to rosuvastatin improves endothelial dependent and independent vasodilatation as well as further improves the lipid profile in South Asians with dyslipidemia. These vasodilative effects are lost with the removal of omega-3 PUFAs. Population studies and clinical trials provide compelling evidence that omega-3 PUFAs have significant cardioprotective effects and justify their use in the prevention of cardiovascular diseases. These benefits are achieved without the known side effects of other drug combinations. The present study also suggests that omega-3 PUFA's are not only effective triglyceride-lowering agents but also improve endothelial function in a group of subjects resistant to the vasoactive effect of rosuvastatin.
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![Study design: An open-label, randomized cross-over study. Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only.\
**Abbreviations:** Ro, rosuvastatin; Omega-3 PUFAs, Omega-3 polyunsaturated fatty acids.](vhrm-4-1439f1){#f1-vhrm-4-1439}

![Average endothelial dependent vasodilation percentage (EDV%) for groups 1 and 2 during each visit. Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only. Data represent mean per group ± SE.\
**Notes:** \*indicates statistical significance difference of average EDV% between each visit by Wilcoxon test.](vhrm-4-1439f2){#f2-vhrm-4-1439}

![Average endothelial independent vasodilation percentage (EIV%) for groups 1 and 2 during each visit. Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs. Group 2 represents patients starting with rosuvastatin only. Data represent mean per group ± SE.\
**Note:** \*indicates statistical significance difference of average EDV% between each visit by Wilcoxon test.](vhrm-4-1439f3){#f3-vhrm-4-1439}

![Lipid profile (including total cholesterol (TCh), high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides (TG) for groups 1 and 2 at baseline (b), visit 1 (1), and visit 2 (2). Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs. Group 2 represents patients starting with rosuvastatin only. Data represent mean per group ± SE.\
**Note:** \*indicates statistical significance (by t test) between each visit.](vhrm-4-1439f4){#f4-vhrm-4-1439}

![Plotted results of endothelium dependent vasodilation percentage (EDV%) for each individual patient in group 1 and 2 between each visit. Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only.](vhrm-4-1439f5){#f5-vhrm-4-1439}

###### 

Baseline characteristics of the study subjects

  Characteristics                 Group 1 (n = 14)                        Group 2 (n = 16)                        P value
  ------------------------------- --------------------------------------- --------------------------------------- ---------
  Age (years), mean (range)       51 (27--78)                             52 (28--73)                             NS
  Gender: Male (n, %)             12 (86)                                 11 (69)                                 NS
    Female (n, %)                 2 (14)                                  5 (31)                                  NS
  BMI, mean (kg/m^2^)             27 ± 4.2                                27.2 ± 4.7                              NS
  Dyslipidemia (n, %)             14 (100)                                16 (100)                                NS
  Metabolic syndrome (n, %)       11 (79)                                 16 (100)                                NS
  CAD (n, %)                      9 (64)                                  11 (69)                                 NS
  Diabetes (n, %)                 5 (36)                                  5 (31)                                  NS
  HTN (n, %)                      9 (64)                                  12 (75)                                 NS
  Medications                                                                                                     
    ASA (n, %)                    9 (64)                                  13 (81)                                 NS
    Clopidogrel (n, %)            7 (50)                                  8 (50)                                  NS
    Beta blocker (n, %)           9 (64)                                  9 (56)                                  NS
    ACE inhibitor or ARB (n, %)   7 (50)                                  10 (63)                                 NS
    Statin                        4-week washout prior to randomization   4-week washout prior to randomization   

**Notes:** Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only. Data are presented as n or mean ± SD. Comparison between groups was done by chi-square test or t-test for age and BMI.

**Abbreviations:** NS, nonsignificant; BMI, body mass index; CAD, coronary artery disease; HTN, hypertension; ASA, aspirin; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; PUFAs, polyunsaturated fatty acids; SD, standard deviation.

###### 

Laboratory values

                              Group 1       Group 2                                                
  --------------------------- ------------- ------------- ------------- ------------ ------------- -------------
  Total cholesterol (mg/dl)   191 ± 44      153 ± 37\*    159 ± 35\*    184 ± 40     159 ± 54      139 ± 31\*
  HDL (mg/dl)                 42 ± 12       43 ± 13       44 ± 14       41 ± 15      40 ± 10       43 ± 15
  LDL (mg/dl)                 116 ± 37      88 ± 29\*     96 ± 36       109 ± 31     91 ± 41       76 ± 24\*
  Triglycerides (mg/dl)       139 ± 57      91 ± 40\*     99 ± 27\*     137 ± 71     141 ± 71      103 ± 36\*
  Glucose (mg/dl)             124 ± 54      130 ± 62      112 ± 30      104 ± 24     108 ± 39      110 ± 38
  Hemoglobin A~1~C (%)        7.0 ± 2.2     7.0 ± 2.2     6.6 ± 1.8     6.5 ± 1.1    6.3 ± 1.0     6.2 ± 1.0
  Fibrinogen (mg/dl)          357 ± 72      348 ± 70      338 ± 68      357 ± 87     352 ± 70      333 ± 69
  C-reactive protein (mg/l)   0.36 ± 0.41   0.3 ± 0.36    0.34 ± 0.46   0.4 ± 0.46   0.25 ± 0.23   0.19 ± 0.17
  ESR (mm/hr)                 16 ± 13       14 ± 12       12 ± 9        18 ± 13      14 ± 11       9 ± 9
  Adiponectin (μg/ml)         8.63 ± 3.56   9.06 ± 4.75   8.98 ± 4.16   6.46 ± 4.4   6.22 ± 3.98   6.43 ± 4.6
  BP Systolic (mmHg)          119 ± 10      112 ± 12      122 ± 16      127 ± 22     131 ± 17      132 ± 16
  BP Diastolic (mmHg)         71 ± 7        69 ± 10       77 ± 9        75 ± 11      80 ± 10       77 ± 5

**Notes:** Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs. Group 2 represents patients starting with rosuvastatin only. Data are presented as mean ±SD. Statistically significant differences are indicated with an asterisk.

**Abbreviations:** HDL, high-density lipoprotein; LDL, low-density lipoprotein; ESR, erythrocyte sedimentation rate; BP, blood pressure; PUFAs, polyunsaturated fatty acids; SD, standard deviation.

###### 

Assessment of endothelial function by brachial artery ultrasound

                          Group 1        Group 2                                                        
  ----------------------- -------------- ---------------- -------------- -------------- --------------- -----------------
  Diameter (mm)           Baseline       1st visit        2nd visit      Baseline       1st visit       2nd visit
  Resting                 3.9 ± 0.6      3.7 ± 0.7        3.7 ± 0.7      3.7 ± 0.7      3.6 ± 0.6       3.1 ± 0.6
  Post-ischemic maximum   3.9 ± 0.5      4.1 ± 0.7        3.7 ± 0.7      3.6 ± 0.8      3.6 ± 0.7       3.6 ± 0.7
  Absolute EDV            −0.06 ± 0.13   0.41 ± 0.17\*    0.007 ± 0.31   −0.09 ± 0.15   −0.006 ± 0.21   0.44 ± 0.31\*
  \% EDV                  −1.42 ± 3.27   11.36 ± 4.33\*   0.59 ± 8.32    −2.49 ± 4.16   −0.66 ± 6.44    14.73 ± 10.77\*
  Post-nitroglycerine     3.9 ± 0.8      4.2 ± 0.8        4.0 ± 0.7      3.9 ± 0.6      4.0 ± 0.7       4.0 ± 0.8
  Absolute EIV            0.11 ± 0.23    0.59 ± 0.26\*    0.3 ± 0.27     0.33 ± 0.32    0.38 ± 0.36     0.77 ± 0.33\*
  \% EIV                  3.4 ± 7.67     17.37 ± 9.27\*   8.71 ± 7.67    10.31 ± 9.62   11.02 ± 10.43   24.5 ± 11.94\*

**Notes:** Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs. Group 2 represents patients starting with rosuvastatin only. Data are presented as mean ± SD. Statistically significant differences are indicated with an asterisk.

**Abbreviations:** EDV, endothelial-dependent vasodilation; EIV, endothelial-independent vasodilation; PUFAs, polyunsaturated fatty acids; SD, standard deviation.
